News round-up by DDW’s Reece Armstrong for 8-12 August
New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up.
Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva.
Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.
Clinical stage biotech company Oxeia Biopharmaceuticals has announced interim results from a Phase II trial investigating its treatment for concussion.
Life sciences company PerkinElmer will divest its Applied, Food and Enterprise Services to the private equity firm New Mountain Capital in a potential deal worth $2.45 billion.
Scientists have discovered how melanoma skin cancer cells invade new tissues in research they hope might lead to new treatments.